The Determination of the Levels of Circulating Galectin-1 and -3 in HNSCC Patients Could Be Used to Monitor Tumor Progression and/or Responses to Therapy
Saussez, Sven ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale
Lorfevre, François
Lequeux, Thomas
Laurent, Guy ; Université de Mons > Faculté de Médecine et de Pharmacie > Histologie
Chantrain, Gilbert
Vertongen, Françoise
Toubeau, Gérard
Decaestecker, Christine
Kiss, Robert
Language :
English
Title :
The Determination of the Levels of Circulating Galectin-1 and -3 in HNSCC Patients Could Be Used to Monitor Tumor Progression and/or Responses to Therapy
Publication date :
01 January 2008
Journal title :
Oral Oncology
ISSN :
1368-8375
Publisher :
Elsevier, United Kingdom
Volume :
44
Pages :
86-93
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M112 - Anatomie humaine et Oncologie expérimentale M118 - Histologie
Hunter K.D., Parkinson E.K., and Harrison P.R. Profiling early head and neck cancer. Nat Rev Cancer 5 (2005) 127-135
Grandis J.R., Pietenpol J.A., Greeberger J.S., Pelroy R.A., and Mohla S. Head and neck cancer: meeting summary and research opportunities. Cancer Res 64 (2004) 8126-8129
Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 350 (2004) 1937-1944
Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefebvre J.L., Grenier R.H., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002;19;1572:285-93.
Liu F.T., and Rabinovich G.A. Galectins as modulators of tumour progression. Nat Rev Cancer 5 (2005) 29-41
Saussez S, Camby I, Toubeau G, Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas (HNSCCs). Head & Neck [in press].
Camby I., Le Mercier M., Lefranc F., and Kiss R. Galectin-1: S small protein with major functions. Glycobiology 16 (2006) 137-157
Nakahara S., Oka N., and Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 10 (2005) 267-275
Dumic J., Dabelic S., and Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 1760 (2006) 616-635
Saussez S., and Kiss R. Galectin-7. Cell Mol Life Sci 63 (2006) 686-697
He Q.Y., Chen J., Kung H.F., Yuen A.P., and Chiu J.F. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 4 (2004) 271-278
Le Q.T., Shi G., Cao H., Nelson D.W., Wang Y., Chen E.Y., et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23 (2005) 8932-8941
Saussez S., Cucu R., Decaesteker C., Chevalier D., Kaltner H., André S., et al. Galectin-7 (p53-induced gene-1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 13 (2006) 999-1009
Choufani G., Nagy N., Saussez S., Marchant H., Biscchop P., Burchert M., et al. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86 (1999) 2353-2563
Honjo Y., Inohara H., Akahani S., Yoshi T., Takenaka Y., Yoshida J., et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6 (2000) 4635-4640
Plzak J., Betka J., Smetana Jr. K., Chovanec M., Kaltner H., André S., et al. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 40 (2004) 2324-2330
Piantelli M., Iacobelli S., Almadori G., Iezzi M., Tinari N., Natoli C., et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 20 (2002) 3850-3856
Chen J., He Q.Y., Yuen A.P., and Chiu J.F. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 4 (2004) 2465-2475
Iurisci I., Tinari N., Natoli C., Angelucci D., Cianchetti E., and Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6 (2000) 1389-1393
Jokilehto T., Rantanen K., Luukkaa M., Heikinen P., Grenman R., Minn H., et al. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 12 (2006) 1080-1087
Koukourakis M.I., Bentzen S.M., Giatromanolaki A., Wilson G.D., Daley F.M., Saunders M.I., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarrequi J.M., Bravo A., et al. Targeted inhibition of Galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004) 241-251
Wu C.C., Chien K.Y., Tsang N.M., Chang K.P., Hao S.P., Tsao C.H., et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 5 (2005) 3173-3182
Delorge S., Saussez S., Pelc P., Devroede B., Marchant H., Burchert M., et al. Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 122 (2000) 834-841
Plzak J., Smetana Jr. K., Hrdlickova E., Kodet R., Holikova Z., Liu F.T., et al. Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation. Int J Oncol 19 (2001) 59-64
Nickel W. The mystery of nonclassical protein secretion. Eur J Biochem 270 (2003) 2109-2119